↓ Skip to main content

Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases

Overview of attention for article published in Frontiers in Pharmacology, February 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

news
1 news outlet
twitter
6 X users
patent
1 patent
wikipedia
1 Wikipedia page
reddit
1 Redditor

Citations

dimensions_citation
56 Dimensions

Readers on

mendeley
182 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Animal Toxins as Therapeutic Tools to Treat Neurodegenerative Diseases
Published in
Frontiers in Pharmacology, February 2018
DOI 10.3389/fphar.2018.00145
Pubmed ID
Authors

Jessica M. de Souza, Bruno D. C. Goncalves, Marcus V. Gomez, Luciene B. Vieira, Fabiola M. Ribeiro

Abstract

Neurodegenerative diseases affect millions of individuals worldwide. So far, no disease-modifying drug is available to treat patients, making the search for effective drugs an urgent need. Neurodegeneration is triggered by the activation of several cellular processes, including oxidative stress, mitochondrial impairment, neuroinflammation, aging, aggregate formation, glutamatergic excitotoxicity, and apoptosis. Therefore, many research groups aim to identify drugs that may inhibit one or more of these events leading to neuronal cell death. Venoms are fruitful natural sources of new molecules, which have been relentlessly enhanced by evolution through natural selection. Several studies indicate that venom components can exhibit selectivity and affinity for a wide variety of targets in mammalian systems. For instance, an expressive number of natural peptides identified in venoms from animals, such as snakes, scorpions, bees, and spiders, were shown to lessen inflammation, regulate glutamate release, modify neurotransmitter levels, block ion channel activation, decrease the number of protein aggregates, and increase the levels of neuroprotective factors. Thus, these venom components hold potential as therapeutic tools to slow or even halt neurodegeneration. However, there are many technological issues to overcome, as venom peptides are hard to obtain and characterize and the amount obtained from natural sources is insufficient to perform all the necessary experiments and tests. Fortunately, technological improvements regarding heterologous protein expression, as well as peptide chemical synthesis will help to provide enough quantities and allow chemical and pharmacological enhancements of these natural occurring compounds. Thus, the main focus of this review is to highlight the most promising studies evaluating animal toxins as therapeutic tools to treat a wide variety of neurodegenerative conditions, including Alzheimer's disease, Parkinson's disease, brain ischemia, glaucoma, amyotrophic lateral sclerosis, and multiple sclerosis.

X Demographics

X Demographics

The data shown below were collected from the profiles of 6 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 182 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 182 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 36 20%
Student > Master 24 13%
Student > Ph. D. Student 20 11%
Researcher 16 9%
Student > Doctoral Student 8 4%
Other 24 13%
Unknown 54 30%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 34 19%
Agricultural and Biological Sciences 18 10%
Medicine and Dentistry 17 9%
Neuroscience 12 7%
Pharmacology, Toxicology and Pharmaceutical Science 12 7%
Other 28 15%
Unknown 61 34%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 January 2024.
All research outputs
#1,883,185
of 25,366,663 outputs
Outputs from Frontiers in Pharmacology
#755
of 19,589 outputs
Outputs of similar age
#39,554
of 336,962 outputs
Outputs of similar age from Frontiers in Pharmacology
#30
of 343 outputs
Altmetric has tracked 25,366,663 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 19,589 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.3. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 336,962 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 343 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.